Phase II trial of idarubicin, fludarabine, Ara-C, and filgrastim filgrastim (G-CSF) (Ida-FLAG) for treatment of poor prognosis acute myeloid leukemia (AML).

被引：0
|
作者：
Wickramanayake, PD [1 ]
Steinmetz, HT [1 ]
Katay, I [1 ]
Glasmacher, A [1 ]
Staib, P [1 ]
Diehl, V [1 ]
机构：
[1] UNIV HOSP KOLN,DEPT INTERNAL MED 1,COLOGNE,GERMANY
来源：
BLOOD | 1995年 / 86卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：3009 / 3009
页数：1
相关论文
共 50 条
  • [31] Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of acute myeloid leukemia relapsing after autologous stem cell transplantation
    Ferrara, F
    Melillo, L
    Montillo, M
    Leoni, F
    Pinto, A
    Mele, G
    Mirto, S
    ANNALS OF HEMATOLOGY, 1999, 78 (08) : 380 - 384
  • [32] Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of acute myeloid leukemia relapsing after autologous stem cell transplantation
    F. Ferrara
    L. Melillo
    M. Montillo
    F. Leoni
    A. Pinto
    G. Mele
    S. Mirto
    Annals of Hematology, 1999, 78 : 380 - 384
  • [33] CURATIVE EFFECT AND SAFETY OF 2-CDA, ARA-C AND G-CSF COMBINED TREATMENT FOR RELAPSED REFRACTORY ACUTE MYELOID LEUKEMIA
    Zhang, Xiaoxiang
    Chen, Ying
    Shou, Lihong
    Yang, Jianghua
    ACTA MEDICA MEDITERRANEA, 2021, 37 (01): : 163 - 167
  • [34] Topotecan, fludarabine, Ara-C and G-CSF (T-FLAG) for aggressive myelodysplastic syndromes and acute myelogenous leukemia in the elderly: A dose finding for topotecan study.
    Besa, EC
    Roda, P
    Woodland, C
    Dourado, C
    BLOOD, 2000, 96 (11) : 259B - 259B
  • [35] The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients
    Ossenkoppele, GJ
    Graveland, WJ
    Sonneveld, P
    Daenen, SMGJ
    Biesma, DH
    Verdonck, LF
    Schaafsma, R
    Westveer, PHM
    Peters, F
    Noordhuis, P
    Muus, P
    van der Holt, R
    Delforge, M
    Löwenberg, B
    Verhoef, GEG
    BLOOD, 2004, 103 (08) : 2908 - 2913
  • [36] Modulation of high dose Ara-C metabolism in acute myeloid leukemia by hematopoietic growth factors (G-CSF; GM-CSF) and ribonucleotide reductase inhibitors (fludarabine; gemcitabine).
    Braess, J
    Wegendt, C
    Jahns-Streubel, G
    Hidemann, W
    Kern, W
    Unterhalt, M
    Schleyer, E
    BLOOD, 1998, 92 (10) : 385A - 385A
  • [37] Phase II study of cladribine, idarubicin, and ara-C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemia
    Kadia, Tapan M.
    Ravandi, Farhad
    Molica, Matteo
    Bataller, Alex
    Borthakur, Gautam
    Daver, Naval
    Jabbour, Elias
    Dinardo, Courtney D.
    Pemmaraju, Naveen
    Jain, Nitin
    Ferrajoli, Alessandra
    Ylimaz, Musa
    Bose, Prithviraj
    Tidwell, Rebecca Slack
    Marx, Kayleigh R.
    Rausch, Caitlin R.
    Kanagal-Shamanna, Rashmi
    Wang, Sa
    Islam, Rabiul
    Champlin, Richard
    Shpall, Elizabeth
    Konopleva, Marina
    Garcia-Manero, Guillermo
    Kantarjian, Hagop
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 (11) : 1711 - 1720
  • [38] Phase II Study of Vorinostat in Combination with Idarubicin (Ida) and Cytarabine (ara-C) as Front Line Therapy in Acute Myelogenous Leukemia (AML) or Higher Risk Myelodysplastic Syndrome (MDS).
    Garcia-Manero, Guillermo
    Tambaro, Francesco Paolo
    Bekele, B. Nebiyou
    Jabbour, Elias
    Ravandi, Farhad
    Yang, Hui
    Borthakur, Gautam
    Kadia, Tapan
    Cortes, Jorge
    Faderl, Stefan
    Konopleva, Marina
    Pierce, Sherry
    Burger, Jan A.
    Estrov, Zeev
    O'Brien, Susan
    Thomas, Deborah
    Newsome, Willie
    Kantarjian, Hagop
    BLOOD, 2009, 114 (22) : 436 - 436
  • [39] FLUDARABINE, CYTARABINE, GRANULOCYTE COLONY-STIMULATING FACTOR, AND IDARUBICIN (FLAG-IDA) FOR THE TREATMENT OF CHILDREN WITH POOR-PROGNOSIS ACUTE LEUKEMIA: The Hacettepe Experience
    Tavil, Betul
    Aytac, Selin
    Balci, Yasemin Isik
    Unal, Sule
    Kuskonmaz, Baris
    Yetgin, Sevgi
    Gurgey, Aytemiz
    Tuncar, Murat
    Gumruk, Fatma
    Uckan, Duygu
    Cetin, Mualla
    PEDIATRIC HEMATOLOGY AND ONCOLOGY, 2010, 27 (07) : 517 - 528
  • [40] Pilot trial of imatinib, low-dose cytarabine (ara-C) and idarubicin (Ida) in patients (pts) with chronic myeloid leukemia (CML) in myeloid blastic phase (BP).
    Quintas-Cardama, A
    Kantarjian, H
    Ravandi, F
    Garcia-Manero, G
    O'Brien, S
    Wierda, W
    Faderl, S
    Cortes, J
    BLOOD, 2005, 106 (11) : 290B - 290B
12345